Clinical Trial Update: STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling [Phase 2]

View source ↗

Summary

Phase 2 study of STA-9090 (ganetespib) in castration-resistant prostate cancer was withdrawn. The trial included assessment of androgen receptor pathway signali…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• STA-9090 (ganetespib) (ganetespib)

Snippet

Sponsor: Toni Choueiri, MD | Conditions: Adenocarcinoma of the Prostate | Phase 2 | Status: WITHDRAWN